Sustainability Report

Overview

The report presents Tabuk Pharmaceuticals' first consolidated sustainability account for 2024, covering all worldwide operations and 1,942 employees. It reports Scope 1 emissions of 3,032 tonnes CO2e, market-based Scope 2 emissions of 14,230 tonnes CO2e, and Scope 3 emissions of 35,050 tonnes CO2e, with combined Scope 1 and 2 emissions reduced by 19.6% since 2021. Resource indicators include 175.64 tonnes of total waste, 23.1% waste recycling, and 1.27% renewable energy use. Sustainability oversight sits with the Senior Executive Team and relevant Board Committees, and the report is prepared in partial accordance with GRI Standards.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level
CDP score

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services